📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Modalities
Get in touch
Background

modalities

Biologics

Advancing biologics through cutting-edge design, structural biology, and chemistry for next-generation therapeutics.

Get in touch

supporting your research

Sygnature Discovery supports the full spectrum of biologics discovery from early concept through candidate nomination.

Our scientists draw on deep biological insight with practical expertise across bioscience, in vivo pharmacology, and DMPK to deliver innovation.

Working across oncology, inflammation, neuroscience, and metabolic disease, we design and optimize biologic molecules including monoclonal antibodies, peptides, nucleic acids, and cell and gene therapies that effectively translate from bench to clinic, ensuring a smooth and efficient path from idea to candidate.

3D rendering of monoclonal antibodies interacting with antigens, representing biologics drug discovery and advanced therapeutic development.

Our Approach to Biologics Discovery

Every biologic demands a tailored strategy. Whether developing antibodies, peptides, nucleic acids, or cell and gene therapies, our multidisciplinary teams build robust, flexible workflows for each program.

Collaboration underpins everything we do, bioscientists, protein engineers, in vivo pharmacologists, and DMPK specialists work in unison to deliver rapid, decision-enabling data. By integrating scientific excellence with agility and partnership, we help clients realize the full potential of biologics.

how we can help

Why choose Sygnature Discovery?

We combine scientific depth, cutting-edge technology, and a collaborative mindset to help our partners unlock the promise of biologics. Working across key therapeutic areas, we deliver innovative solutions that go beyond traditional approaches, accelerating development and advancing novel modalities toward the clinic.

At Sygnature Discovery, we turn complex ideas into effective new medicines that change lives.

Case Studies

Trusted by customers worldwide

 

Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.

From Lead to Pre-Candidate Nomination in 18 Months

Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.

Read the case study

Sitryx: Empowering New Ideas

Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.

Read the case study

Rapid creation of ideas using generative AI (GenAI) with Iktos Makya

Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.

Read the case study

Corcept Therapeutics: Integrated Drug Discovery Collaboration

Corcept Therapeutics, located in Menlo Park, CA, is a leader in the discovery and development of drugs that regulate the effects of cortisol.

Read the case study

CellCentric Lead Optimisation Campaign – CCS1477

CellCentric are developing new treatments for cancer based on their understanding of epigenetics.

Read the case study

Fragment-based hit discovery for the epigenetic target, BRD3

Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.

Read the case study

Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates

UK-based small molecule drug discovery company

Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD

Read the case study